Shilpa Medicare Ltd Stock Price Today (NSE: SHILPAMED)
Fundamental Score
Shilpa Medicare Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Shilpa Medicare Ltd share price today is ₹611.25, up +1.10% on NSE/BSE as of 31 July 2026. Shilpa Medicare Ltd (SHILPAMED) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹12.63K (Cr). The 52-week high for SHILPAMED share price is ₹949.90 and the 52-week low is ₹259.50. At a P/E ratio of 54.12x, SHILPAMED is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 9.40% and a debt-to-equity ratio of 0.25.
Shilpa Medicare Ltd Share Price Chart — NSE/BSE Historical Performance
Shilpa Medicare Ltd share price chart: 7.10% return over the past month. 52-week high ₹949.90, 52-week low ₹259.50.
Shilpa Medicare Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹604.40 | ₹614.95 | ₹601.15 | ₹611.25 | 4.86L (Cr) | |
| ₹612.00 | ₹616.30 | ₹600.10 | ₹604.60 | 3.83L (Cr) | |
| ₹625.00 | ₹625.25 | ₹600.55 | ₹605.20 | 4.34L (Cr) | |
| ₹615.00 | ₹626.50 | ₹607.10 | ₹620.60 | 3.05L (Cr) | |
| ₹630.00 | ₹642.00 | ₹615.20 | ₹640.00 | 5.09L (Cr) | |
| ₹620.80 | ₹636.25 | ₹618.10 | ₹625.45 | 4.14L (Cr) | |
| ₹635.00 | ₹638.00 | ₹617.10 | ₹620.25 | 4.85L (Cr) | |
| ₹644.90 | ₹644.90 | ₹630.50 | ₹637.85 | 3.88L (Cr) | |
| ₹630.00 | ₹650.00 | ₹622.00 | ₹624.25 | 9.55L (Cr) | |
| ₹624.05 | ₹634.00 | ₹615.85 | ₹630.20 | 3.83L (Cr) |
Shilpa Medicare Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹588.00 | ₹650.00 | ₹561.50 | ₹611.25 | +3.95% | |
| ₹504.50 | ₹615.00 | ₹493.40 | ₹598.40 | +18.61% | |
| ₹406.65 | ₹529.80 | ₹406.65 | ₹498.95 | +22.70% | |
| ₹360.00 | ₹436.40 | ₹350.60 | ₹406.65 | +12.96% | |
| ₹315.90 | ₹365.00 | ₹308.30 | ₹348.90 | +10.45% | |
| ₹288.00 | ₹350.90 | ₹272.00 | ₹336.65 | +16.89% | |
| ₹320.00 | ₹324.55 | ₹259.50 | ₹288.95 | -9.70% | |
| ₹343.20 | ₹353.45 | ₹313.15 | ₹321.15 | -6.42% | |
| ₹357.30 | ₹415.00 | ₹340.00 | ₹341.50 | -4.42% | |
| ₹380.00 | ₹407.70 | ₹342.00 | ₹352.85 | -7.14% | |
| ₹849.00 | ₹863.00 | ₹374.00 | ₹376.60 | -55.64% | |
| ₹883.75 | ₹949.90 | ₹796.00 | ₹846.25 | -4.24% |
AI Research Briefing
Powered by Gemini · 2026-04-13
Overvalued and burdened by debt, Shilpa Medicare's future hinges on a successful merger fraught with regulatory and financial risks.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Shilpa Medicare received NCLT approval for its merger with subsidiary Shilpa Therapeutics. The merger's effective date is April 1, 2025, contingent on ROC filing. NCLT requires Shilpa Medicare to settle outstanding dues, including for Shilpa Therapeutics and for Shilpa Medicare, plus MSME dues. Shilpa Medicare reported QOQ increase in revenue of 10.75% and net profit increase of 1.16%.
CORE STORY (THE REAL GAME)
Shilpa Medicare is attempting to consolidate its business and streamline operations through mergers, while navigating regulatory hurdles and managing its debt obligations in a competitive pharma landscape.
- NCLT approval of Shilpa Therapeutics merger
- Recent quarterly results showing revenue growth
- Technical outperformance on April 1, 2026
- Successful ROC filing and completion of merger
- Significant order wins in key therapeutic areas
- Positive developments from India Pharma 2026
- High P/E ratio compared to industry average
- Negative free cash flow
- Need to settle outstanding dues related to merger
FII holdings decreased by 0.27%, while DII holdings increased by 0.21%.
Indian pharma industry is transitioning towards API backward integration, but faces export setbacks due to supply chain issues.
No (Free Cash Flow 5Y: ₹-733.47 Cr)
Shilpa Medicare's 3-6 month outlook depends on successful merger integration and debt management. Failure to execute could lead to significant downside.
Primary Thesis Risk
Failure to successfully integrate Shilpa Therapeutics and manage debt will sink the stock.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Shilpa Medicare Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Shilpa Medicare Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SHILPAMED across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Strong Operating Margins (20.97%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (147.82%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (32.09%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Strong Profit Growth Track Record (17.85% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.25)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (5.82x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Risk Factors
3 factors identified
Below-Average Return on Equity (9.40%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Premium Valuation Risk (P/E: 54.12x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Negative Free Cash Flow (₹-446.17 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Shilpa Medicare Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Shilpa Medicare Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Shilpa Medicare LtdShilpa Medicare...Selected✓ SHILPAMED • 530549 | 53.2/100 | ₹611.25₹611 | ₹12626.67₹12626.67 | 54.12Average 54.1 Average | 9.40%Poor 9.40% Poor | 11.03%Average 11.03% Average | 0.25Excellent 0.3 Excellent | 17.85%Excellent 17.85% Excellent | 11.35%Good 11.35% Good | 0.08% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Shilpa Medicare Ltd PE Ratio History
Historical price-to-earnings ratio for SHILPAMED — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹8.04 | ₹321.15 | 39.9x |
| FY 2024 | ₹3.67 | ₹815.50 | 222.2x |
| FY 2022 | ₹7.26 | ₹278.35 | 38.3x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Shilpa Medicare Ltd Dividend History
Annual cash dividends paid by SHILPAMED — dividend yield 0.08%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2023 | ₹9.55 Cr |
| FY 2022 | ₹8.97 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Shilpa Medicare Ltd Quarterly Performance
Latest quarterly metrics for SHILPAMED — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
32.09%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
147.82%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
11.35%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
17.85%
Compounded annual net profit growth over 5 years
Shilpa Medicare Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for SHILPAMED — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Shilpa Medicare Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Shilpa Medicare Ltd (SHILPAMED) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Shilpa Medicare Ltd
About SHILPAMED (Shilpa Medicare Ltd)
Shilpa Medicare Ltd is a global pharmaceutical company with a prominent footprint in oncology and specialty therapeutics. The company distinguishes itself through its comprehensive... range of capabilities, encompassing the entire pharmaceutical value chain, from the development and manufacture of active pharmaceutical ingredients (APIs) to the production of finished dosage formulations and innovative biosimilars. Shilpa Medicare focuses on cutting-edge research and development, aiming to provide high-quality, affordable medicines that address unmet medical needs across a diverse range of therapeutic areas. It emphasizes sustainable practices and aims to adhere to global regulatory standards in all aspects of its operations. Shilpa Medicare operates through diverse divisions, including API manufacturing, formulations production, and biosimilar development. Its API portfolio includes a wide array of both oncology and non-oncology ingredients, catering to the requirements of pharmaceutical companies across the globe. The company's finished dosage formulation unit produces a broad spectrum of therapeutic options, while its biosimilars division is focused on developing and commercializing cost-effective alternatives to complex biologic drugs. Shilpa Medicare strategically invests in advanced technology and infrastructure to support its manufacturing activities and ensures consistent product quality and reliability. Shilpa Medicare's commercial presence spans across multiple continents, with a dedicated focus on expanding its reach in key markets such as India, the United States, and Europe. The company fosters strategic partnerships and collaborations to accelerate its growth and strengthen its market position. By integrating technological advancements, scientific expertise, and a strong focus on customer satisfaction, Shilpa Medicare strives to contribute significantly to the advancement of healthcare worldwide. It aims to continuously innovate and improve its products and services to meet the evolving needs of patients and healthcare providers.
Company Details
Key Leadership
Corporate Events
SHILPAMED Share Price: Frequently Asked Questions
What is the current share price of Shilpa Medicare Ltd?
Shilpa Medicare Ltd (SHILPAMED) trades at ₹611.25 on NSE and BSE. Market cap ₹12.63K (Cr). Educational data only.
What is the P/E ratio of Shilpa Medicare Ltd?
Shilpa Medicare Ltd has a P/E of 54.12x vs industry average 34.89x.
What is the Bull Run score for Shilpa Medicare Ltd?
Shilpa Medicare Ltd has a Bull Run score of 53.2/100 based on 25+ financial parameters.
Does Shilpa Medicare Ltd pay dividends?
Shilpa Medicare Ltd has a dividend yield of 0.08%. Past dividends don't guarantee future payments.
What is the ROE of Shilpa Medicare Ltd?
Shilpa Medicare Ltd has ROE of 9.40%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Shilpa Medicare Ltd?
Shilpa Medicare Ltd has debt-to-equity of 0.25.
Is Shilpa Medicare Ltd a good investment?
Bull Run gives Shilpa Medicare Ltd a score of 53.2/100. This is not investment advice — consult a SEBI-registered advisor.